Navigation Links
Lipodissolve - Is it Safe???
Date:9/24/2007

President of National Cosmetic Dermatology Organization Urges Consumers to

Beware!

OMAHA, Neb., Sept. 24 /PRNewswire/ -- Joel Schlessinger, M.D., President of the American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS), responded to the recent decision by Judge David Bruns to block the proposal by the Kansas State Board of Healing Arts to ban the liposuction treatment, Lipodissolve. "This procedure is still unsafe in my estimation and has the potential to cause significant harm, especially given its poor track record in Europe, Brazil and Canada," the board-certified dermatologist and general cosmetic surgeon said.

The safety of Lipodissolve, a treatment involving a series of injections of a mixture of phosphatidylcholine and sodium deoxycholate (PC/DC) to break down body fat, has long been criticized as unstudied by medical entities. In addition to Schlessinger's statement on behalf of ASCDAS, the American Society of Plastic Surgeons and the American Society of Dermatologic Surgeons have also released statements against the use and practice of Lipodissolve. The proposed ban by the Kansas State Board of Healing Arts was the first of its kind in the United States, and followed the lead of Brazil, Canada and the United Kingdom in banning Lipodissolve treatments. "The decision to reverse the Kansas block on Lipodissolve unfortunately goes against FDA statements regarding the safe and responsible practices of cosmetic dermatology," states Schlessinger.

"I am quite concerned that this process is going on in a wide variety of unregulated settings. Many cases have come to my attention where patients suffered long-term consequences, most of the time without having any idea of the potential for problems prior to having treatments performed" said Joel Schlessinger M.D. "Additionally, the individuals administering the procedure are frequently unskilled in sterile technique, the ingredients used in the t
'/>"/>

SOURCE Joel Schlessinger, M.D.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)... As the health care reform details emer...insurance for small groups and business insurance ...re turning to websites such as the Small Business ... Minneapolis, Minn. (PRWEB) Ju...g considered by the House, which has entrepreneurs...
(Date:7/2/2009)..., Fla., July 2 Acetamin...ter and prescription medicines to help relieve pai...ophen by a brand name, Tylenol and prescription br...ry committee for the FDA met on June 30, 2009 to a...etaminophen. The committee voted 20-17 to urge th...
(Date:7/2/2009)...IA, July 2 A new analys...100,000 women between the ages of 0 to 84 from 200...estimates issued by the Ministry of Health, with t...oungest group studied (ages 25 to 44). , , The ...es that track major breast surgeries rather than o...
(Date:7/2/2009)...tions in the DNA of the hepatitis B virus (HBV) ar...and may help predict which patients with HBV infec...ing to a large meta-analysis in the Journal of th...y 2. , HBV infection is a known cause of hepatoc...iver cancer. Previous studies have looked at wheth...
Breaking Medicine News(10 mins):Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 2Health News:Health Care Reform Details Emerge with 'Play or Pay' Requirements, Leaving Some Wondering about Small Business Owner Insurance 3Health News:Viles & Beckman, LLC: Stop Your Headache NOT Your Liver 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 2Health News:Rate of Breast Cancer in Italy Significantly Higher Than Previously Reported 3
...oved a new drug, named YAZ, which can be used as a...r treating acne.// The U.S. Food and Drug Adminis...oman, which can also treat emotional and physical ...ric disorders. The YAZ drug, manufactured by Baye...
...h good and bad news in the report released by the ...report looks at figures representing cases of infe...pital bug, Clostridium difficile and the ‘super bu...ased statistics the figures for Clostridium infect...
...arnataka is planning to enact legislation to make ...and for politicians seeking to enter the state leg...rnment on the need to bring in such a legislation ...r R. Ashok told IANS. Karnataka is one of six high...
...en a forty percent increase in number of cases whe.... This has been due //to non availability of steri...nt Shapps, Conservative MP. According to him the p...ason for this sorry state. This in turn has affect...
Other Medicine News:Health News:Lethal Hospital Bug Tough to Knock Down, Statistics Reveal 2Health News:HIV Tests to Be Made Mandatory for Karnataka Couples, Politicians 2
(Date:6/29/2009)...ajor abdominal surgery patients achieved primary a..., June 29 AcelRx Pharmaceuticals, ...ond Phase 2 clinical study evaluating the safety a...for the management of acute post-operative pain in...alization. Compared to placebo, patients receiving...
(Date:6/28/2009)...NHAM, England and TOKYO, June 29 ,... Companies , Sosei Group Corporation ("Sose...c ("Vectura"; LSE: VEC) announce the commencement ...VA237, a once-daily, long-acting muscarinic,antag...ive pulmonary disease,(COPD). NVA237 is a dry pow...
(Date:6/26/2009)...pinion Recommends Approval of New Anti-TNF Therapy...TM) Autoinjector , , HORSHAM, Pa. and KENILWORT...r Ortho Biotech Inc. and Schering-Plough Corporati...ee for Medicinal Products for Human Use (CHMP) of ...itive opinion recommending the approval of SIMPONI...
(Date:6/25/2009)...and EMBEDA (TM) Data Highlighted at the College on... RENO, Nev., June 25 King Pharma... the Company is presenting safety and efficacy dat...el opioid analgesic formulations that are in devel...on Problems of Drug Dependence. King is also deve...
Breaking Medicine Technology:AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 2AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 3AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain 4Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 2King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 3King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 4King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 5King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use 6Music Can Help Restore Stroke Patients Sight 40674 1Music Can Help Restore Stroke Patients Sight 40674 2Few Hospitals Embracing Electronic Health Record Systems 40669 1Few Hospitals Embracing Electronic Health Record Systems 40669 2Few Hospitals Embracing Electronic Health Record Systems 40669 3Few Hospitals Embracing Electronic Health Record Systems 40669 4Universal Benefit Plans Teams up with Leggette Actuaries to Offer Free COBRA Services to New Clients 40662 1Universal Benefit Plans Teams up with Leggette Actuaries to Offer Free COBRA Services to New Clients 40662 2Above 26 Beyond Citizen Honors Announces and Honors 2009 Recipients 40656 1Above 26 Beyond Citizen Honors Announces and Honors 2009 Recipients 40656 2Above 26 Beyond Citizen Honors Announces and Honors 2009 Recipients 40656 3Above 26 Beyond Citizen Honors Announces and Honors 2009 Recipients 40656 4
...f the Most Challenging Patient Populations,Studied...ARCELONA and MENLO PARK, Calif., May 22, 2007,/PRN...ve six-month,follow-up data from the CUSTOM II cli...y of the company,s investigational Custom,NX(R) dr... long and,multiple lesions in patients with corona...
...USINESS WIRE)--May 22, 2007 - Professor Ian,Meredi...lia, on,Tuesday presented positive nine-month resu...the EuroPCR meeting in Barcelona, Spain,with data...d no,protocol-defined stent thrombosis. The next-g...e drug-eluting stent system with new,BioLinx(TM) p...
Other Medicine Technology:XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 2XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 3XTENT Announces Promising Six-Month Custom II Trial Data Presented,at EuroPCR Meeting 4Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR 2Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR 3
Inquire
Contour I pouches are light as a feather and feature our tapered SoftFlex skin barrier for comformability, flexbility and comfort. All Contour I pouches have ComfortWear panels that keep skin cool an
Inquire
Inquire
Medicine Products: